Abbreviations
- TNF:
-
Tumor necrosis factor
- DILI:
-
Drug induced liver injury
- AIH:
-
Autoimmune hepatitis
References
Subramaniam K, Chitturi S, Brown M. Infliximab-induced autoimmune hepatitis in Crohn’s disease treated with budesonide and mycophenolate. Inflamm Bowel Dis. 2011;17:E149–E150.
Doyle A, Forbes G, Kontorinis N. Autoimmune hepatitis during infliximab therapy for Crohn’s disease: a case report. J Crohns Colitis. 2011;5:253–255.
Goujon C, Dahel K, Bérard F, Guillot I, Gunera-Saad N. Autoimmune hepatitis in two psoriasis patients treated with infliximab. J Am Acad Dermatol. 2010;63:43–44.
Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercep. Clin Rheumatol. 2009;28:1001–1003.
Polin Y, Thérien G. Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review. J Cutan Med Surg. 2010;14:100–104.
Cravo M, Silva R, Serrano M. Autoimmune hepatitis induced by infliximab in a patient with Crohn’s disease with no relapse after switching to adalimumab. Biodrugs. 2010;24:25–27.
Thiéfin G, Morelet A, Heurgué A, Diebold MD, Eschard JP. Infliximab-induced hepatitis. Absence of cross-toxicity with etanercept. Joint Bone Spine. 2008;75:737–739.
Marques M, Magro F, Cardoso H, Carneiro F. Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis. 2008;14:723–725.
Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust. 2007;187:524–526.
Tobon GJ, Cañas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol. 2007;26:578–581.
Germano V, Picchianti A, Baccano G, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis. 2005;64:1519–1520.
Ojiro K, Naganuma M, Ebinuma H, et al. Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab. J Gastroenterol. 2008;43:397–401.
Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis. 2007;13:508–509.
Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn’s disease: need for HBV-screening? World J Gastroenterol. 2006;12:974–976.
Ueno Y, Tanaka S, Shimamoto M, et al. Infliximab therapy for Crohn’s disease in a patient with chronic hepatitis B. Dig Dis Sci. 2005;50:163–165.
Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for and adult onset Still’s disease. J Rheumatol. 2003;30:1624–1625.
Kuwabara H, Fukuda A, Tsuda Y, Shibayama Y. Precore mutant hepatitis B virus associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis. Clin Rheumatol. 2010;29:449–450.
Wahie S, Alexandroff A, Reynolds NJ. Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis. Clin Exp Dermatol. 2006;31:460–461.
Ierardi E, Della Valle N, Nacchiero MC, De Francesco V, Stoppino G, Panella C. Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis. Clin Drug Invest. 2006;26:673–676.
García Aparicio AM, Rey JR, Sanz AH, Alvarez JS. Successful treatment with etanercep in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol. 2007;26:811–813.
Fairhurst A, Sheehan-Dare R. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriasis. Clin Exp Dermatol. 2008;34:402–425.
Kluger N, Girard C, Guillot B, Bessis D. Efficiency and safety of etanercep after acute hepatitis induced by infliximab for psoriasis. Acta Derm-Venereol. 2009;89:332–333.
Soto Fernández S, Gónzalez Carro P, de Pedro Esteban A, et al. Infliximab-induced hepatitis in a patient with Crohn’s disease. Gastroenterol Hepatol. 2006;29:321–322.
Mancini S, Amarotti E, Vecchio S, Ponz de Leon M, Roncucci L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med. 2010;5:193–200.
Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc. 2001;76:84–86.
Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372–374.
Marinos G. TNF receptors in patients with chronic hepatitis B viral infection. Gastroenterology. 1995;108:1453–1463.
Weiler-Normann C, Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol. 2011;55:747–749.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Colina, F., Molero, A., Casís, B. et al. Infliximab-Related Hepatitis: A Case Study and Literature Review. Dig Dis Sci 58, 3362–3367 (2013). https://doi.org/10.1007/s10620-013-2698-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-013-2698-6